AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7924775 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoproteic isocaloric test diet (chicken and fish)
Number of subjects: 15
Study 7924775 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (UD)
Number of subjects: 15
Study 7924775 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (UD) in hyperfiltering group
Number of subjects: 15
Study 7924775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) in hyperfiltering group
Number of subjects: 15
Study 7924775 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoproteic isocaloric test diet (chicken and fish) in hyperfiltering group
Number of subjects: 15
Study 7924775 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (LPD and test diet)
Number of subjects: 15
Study 2894166 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (1 mg once daily, doubled to 1 mg twice daily if BP > 90 mm Hg)
Number of subjects: 58
Study 2894166 — intervention group
Group type: COMPARATOR
Intervention: methyldopa (250 mg twice daily, doubled to 500 mg twice daily if BP > 90 mm Hg)
Number of subjects: 58
Study 31283717 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to home-based rehabilitation
Number of subjects: 88
Study 31283717 — intervention group
Group type: COMPARATOR
Intervention: Low adherence to home-based rehabilitation
Number of subjects: 88
Study 28202896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (ETCO2 45 mmHg)
Number of subjects: 40
Study 28202896 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (ETCO2 35 mmHg)
Number of subjects: 40
Study 28202896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Hypercapnia and Normocapnia)
Number of subjects: 40
Study 25400252 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol treatment
Number of subjects: 176
Study 25400252 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 176
Study 23103798 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (weekly session for 12 weeks)
Number of subjects: 28
Study 23103798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 28
Study 23103798 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (3-month follow-up)
Number of subjects: 28
Study 20825792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 163
Study 20825792 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 163
Study 20825792 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 12.5 mg
Number of subjects: 163
Study 20825792 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 163
Study 18713548 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 50 U three times a week for 12 months
Number of subjects: 148
Study 18713548 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 100 U three times a week for 12 months
Number of subjects: 148
Study 18713548 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral calcium carbonate 1500 mg tid and rocaltrol 0.25 microg qn for 12 months)
Number of subjects: 148
Study 17065354 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine (500 mg p.o. t.i.d. for 6 weeks)
Number of subjects: 40
Study 17065354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14685952 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 61
Study 10910888 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4zeta-modified CD4(+) and CD8(+) T cells with IL-2 (n = 11)
Number of subjects: 24
Study 10910888 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4zeta-modified CD4(+) and CD8(+) T cells without IL-2 (n = 13)
Number of subjects: 24
Study 10910888 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4zeta-modified T cells (both groups)
Number of subjects: 24
Study 10172622 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment
Number of subjects: 0
Study 10172622 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study 1568692 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg slow-release nifedipine (Aprical long 60 mg) administered daily at 1800 hours
Number of subjects: 18
Study 1568692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6206207 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOMLA (doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine)
Number of subjects: 48
Study 6206207 — intervention group
Group type: COMPARATOR
Intervention: CHOP-B (cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin)
Number of subjects: 48
Study 6206207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (ACOMLA and CHOP-B)
Number of subjects: 48
Study 6206207 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular center-cell origin lymphoma
Number of subjects: 48
Study 31286903 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth exercise intervention added to standard care (daily home exercises and weekly therapy sessions)
Number of subjects: 50
Study 31286903 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 50
Study 31286903 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth exercise intervention
Number of subjects: 50
Study 30059843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 812
Study 30059843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study 27635481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 214
Study 27635481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 24044912 — intervention group
Group type: EXPERIMENTAL
Intervention: SWL with simultaneous inversion therapy (30 head down Trendelenburg position)
Number of subjects: 140
Study 24044912 — intervention group
Group type: COMPARATOR
Intervention: SWL with hydration alone
Number of subjects: 140
Study 21751891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone-oxygen treatment
Number of subjects: 61
Study 21751891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham treatment)
Number of subjects: 61
Study 19261730 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 g/d ALA for 6 weeks
Number of subjects: 74
Study 19261730 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 g/d EPA for 6 weeks
Number of subjects: 74
Study 19261730 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 g/d DHA for 6 weeks
Number of subjects: 74
Study 17132119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly stretch intervention (splinted into a stretched, abducted position each night for 12 weeks)
Number of subjects: 44
Study 17132119 — intervention group
Group type: COMPARATOR
Intervention: Control group (not splinted)
Number of subjects: 44
Study 15585769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk
Number of subjects: 31
Study 15585769 — intervention group
Group type: COMPARATOR
Intervention: Nonmilk
Number of subjects: 31
Study 11389292 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pumping using a double electric breast pump for six 10‐ to 15‐minute sessions from 24 to 72 hours postpartum
Number of subjects: 60
Study 11389292 — intervention group
Group type: COMPARATOR
Intervention: Control group held the pump to their breasts without suction for the same amount of time
Number of subjects: 60
Study 11389292 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pumping
Number of subjects: 60
Study 9129472 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled rice-PUFA meal
Number of subjects: 8
Study 9129472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary PUFA
Number of subjects: 8
Study 8101096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg three times daily and 800 mg in the evening on the day preceding ebastine administration and 400 mg four times daily on the 2 following days)
Number of subjects: 12
Study 8101096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 8.2 micron aerodynamic diameter
Number of subjects: 24
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 11.5 micron aerodynamic diameter
Number of subjects: 24
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 13.7 micron aerodynamic diameter
Number of subjects: 24
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 16.4 micron aerodynamic diameter
Number of subjects: 24
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 8.2 micron particles
Number of subjects: 24
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 11.5 micron particles
Number of subjects: 24
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 13.7 micron particles
Number of subjects: 24
Study 3102217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 16.4 micron particles
Number of subjects: 24
Study 797216 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg doxantrazole
Number of subjects: 10
Study 797216 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg doxantrazole
Number of subjects: 10
Study 797216 — intervention group
Group type: COMPARATOR
Intervention: 400 mg doxantrazole three times a day for 14 days
Number of subjects: 10
Study 31548680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid batterer intervention programme (BIP) plus circles of peace (CP)
Number of subjects: 0
Study 31548680 — intervention group
Group type: COMPARATOR
Intervention: Typical batterer intervention programme (BIP)
Number of subjects: 0
Study 28074677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin, Solifenacin, and Trospium
Number of subjects: 452
Study 26033126 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ARDS
Number of subjects: 953
Study 26033126 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ARDS (multicenter study)
Number of subjects: 953
Study 26033126 — intervention group
Group type: COMPARATOR
Intervention: Indirect ARDS
Number of subjects: 953
Study 23910889 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS-loop parameters (maximum vector magnitude, planar area, maximum distance between centroid and loop, perimeter) combined with STC(VM), QRS(VD), and SVG indexes
Number of subjects: 51
Study 21288326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2 drugs added to standard treatment
Number of subjects: 750
Study 21288326 — intervention group
Group type: COMPARATOR
Intervention: Factorial design with one‐ to sixteen‐fold the sample size of the combination trial
Number of subjects: 750
Study 21288326 — intervention group
Group type: COMPARATOR
Intervention: Factorial design with lower sample size
Number of subjects: 750
Study 21288326 — intervention group
Group type: COMPARATOR
Intervention: Adequately powered 2 x 2 factorial design
Number of subjects: 750
Study 19290751 — intervention group
Group type: EXPERIMENTAL
Intervention: Active interventions
Number of subjects: 224
Study 19290751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral strategies
Number of subjects: 224
Study 19290751 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and emotional support
Number of subjects: 224
Study 19290751 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental modifications
Number of subjects: 224
Study 17241408 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 U of BoNTA
Number of subjects: 40
Study 17241408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14614579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 5 days)
Number of subjects: 10
Study 14614579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11299066 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lateral rotation (CLR) with specialized bed
Number of subjects: 19
Study 11299066 — intervention group
Group type: EXPERIMENTAL
Intervention: CLR with P&PD
Number of subjects: 19
Study 11299066 — intervention group
Group type: COMPARATOR
Intervention: Routine turning every 2 h
Number of subjects: 19
Study 11299066 — intervention group
Group type: COMPARATOR
Intervention: Routine turning every 2 h with P&PD
Number of subjects: 19
Study 9397236 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial (RCT) with 10 to 40 mg fosinopril daily
Number of subjects: 2964
Study 9397236 — intervention group
Group type: COMPARATOR
Intervention: Open label trials with 10 to 40 mg fosinopril daily
Number of subjects: 2964
Study 9397236 — intervention group
Group type: EXPERIMENTAL
Intervention: All four study designs (RCT and open trials)
Number of subjects: 2964
Study 9397236 — intervention group
Group type: COMPARATOR
Intervention: Unstructured open trial of 10 to 40 mg fosinopril daily
Number of subjects: 2964
Study 9397236 — intervention group
Group type: COMPARATOR
Intervention: Unstructured open trial
Number of subjects: 2964
Study 7966514 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 pulses at 12.5 KV
Number of subjects: 40
Study 7966514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 pulses at 12.5 KV
Number of subjects: 40
Study 7966514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 pulses at 12.5 KV
Number of subjects: 40
Study 7966514 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 pulses at 12.5 KV
Number of subjects: 40
Study 3308719 — intervention group
Group type: EXPERIMENTAL
Intervention: imidazole salicylate (750 mg t.i.d. per os)
Number of subjects: 60
Study 3308719 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen (600 mg t.i.d. per os)
Number of subjects: 60
Study 31845326 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort self-talk ("I will do my very best!")
Number of subjects: 212
Study 31845326 — intervention group
Group type: COMPARATOR
Intervention: Ability self-talk ("I am very good at this!")
Number of subjects: 212
Study 31845326 — intervention group
Group type: COMPARATOR
Intervention: No self-talk
Number of subjects: 212
Study 29402521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 2.5 mg PO once weekly for 26 weeks
Number of subjects: 395
Study 29402521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 5 mg PO once weekly for 26 weeks
Number of subjects: 395
Study 29402521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 10 mg PO once weekly for 26 weeks
Number of subjects: 395
Study 29402521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 20 mg PO once weekly for 26 weeks
Number of subjects: 395
Study 27221805 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of fragmented Lactobacillus amylovorus CP1563 daily for 12 weeks
Number of subjects: 200
Study 25603130 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporally unpredictable shocks with varying levels of cue unpredictability
Number of subjects: 72
Study 25603130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cue and temporal unpredictability
Number of subjects: 72
Study 25603130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cue and temporal predictability
Number of subjects: 72
Study 25603130 — intervention group
Group type: COMPARATOR
Intervention: Temporally predictable shocks
Number of subjects: 72
Study 23101451 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (STA-MCA bypass)
Number of subjects: 195
Study 23101451 — intervention group
Group type: COMPARATOR
Intervention: Medical group (best medical therapy)
Number of subjects: 195
Study 20038612 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FC-CR formulation 1 (1,500 mg)
Number of subjects: 5
Study 20038612 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FC-CR formulation 2 (1,500 mg)
Number of subjects: 5
Study 20038612 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release 5FC product (Ancobon)
Number of subjects: 5
Study 19159590 — intervention group
Group type: COMPARATOR
Intervention: KIR2DL1 gene phenotype frequency in UC patients (0.710)
Number of subjects: 279
Study 19159590 — intervention group
Group type: COMPARATOR
Intervention: KIR2DL3 gene phenotype frequency in UC patients (0.620)
Number of subjects: 279
Study 19159590 — intervention group
Group type: COMPARATOR
Intervention: KIR2DL1 gene phenotype frequency in CD patients (0.740)
Number of subjects: 279
Study 19159590 — intervention group
Group type: COMPARATOR
Intervention: KIR2DL1 HLA-C2 combination in UC patients (0.380)
Number of subjects: 279
Study 19159590 — intervention group
Group type: COMPARATOR
Intervention: KIR2DL1 HLA-C2 combination in CD patients (0.411)
Number of subjects: 279
Study 16432469 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick, low water content, soft contact lens fitted under a light patch to one eye of diabetic patients
Number of subjects: 46
Study 16432469 — intervention group
Group type: COMPARATOR
Intervention: Thick, low water content, soft contact lens fitted under a light patch to one eye of nondiabetic control subjects
Number of subjects: 46
Study 14983417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 0
Study 14983417 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 0
Study 14983417 — intervention group
Group type: EXPERIMENTAL
Intervention: KHQ (King's Health Questionnaire)
Number of subjects: 0
Study 11771603 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 55
Study 11771603 — intervention group
Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask (ILM)
Number of subjects: 55
Study 9685963 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms Heberbiovac-HB vaccine
Number of subjects: 2
Study 9685963 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms Heberbiovac-HB vaccine
Number of subjects: 2
Study 8314499 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 million units (MU) subcutaneously thrice weekly for four months
Number of subjects: 58
Study 8314499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 58
Study 8314499 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b
Number of subjects: 58
Study 2876497 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin octapeptide (SMS 201-995)
Number of subjects: 13
Study 2876497 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (native hormone)
Number of subjects: 13
Study 28816023 — intervention group
Group type: EXPERIMENTAL
Intervention: Community sensitization sessions
Number of subjects: 0
Study 28816023 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-sensitization survey
Number of subjects: 0
Study 26146964 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identified goals using the Canadian Occupational Performance Measure (COPM)
Number of subjects: 65
Study 26146964 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate UE functional capacity
Number of subjects: 65
Study 26146964 — intervention group
Group type: COMPARATOR
Intervention: Age and UE hand dominance
Number of subjects: 65
Study 24993561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs) program
Number of subjects: 0
Study 24993561 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education
Number of subjects: 0
Study 22525048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.001% twice daily (n = 47)
Number of subjects: 327
Study 22525048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.005% twice daily (n = 48)
Number of subjects: 327
Study 22525048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.005% once daily (n = 44)
Number of subjects: 327
Study 22525048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (all doses)
Number of subjects: 327
Study 22525048 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine 0.05% twice daily (n = 47)
Number of subjects: 327
Study 22525048 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n = 47)
Number of subjects: 327
Study 22525048 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 327
Study 22525048 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 327
Study 22525048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.005% once daily
Number of subjects: 327
Study 19056135 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF treatment
Number of subjects: 59
Study 19056135 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF group
Number of subjects: 59
Study 19056135 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 59
Study 19056135 — intervention group
Group type: EXPERIMENTAL
Intervention: After withdrawal of G‐CSF
Number of subjects: 59
Study 19056135 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentration of SDF-1 at stent implantation
Number of subjects: 59
Study 17719848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia-altitude (n=9)
Number of subjects: 22
Study 17719848 — intervention group
Group type: COMPARATOR
Intervention: Normoxia-altitude (n=6)
Number of subjects: 22
Study 17719848 — intervention group
Group type: COMPARATOR
Intervention: Normoxia-sea level (n=7)
Number of subjects: 22
Study 16339790 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 4 mg kg(‐1) h(‐1) (Group P‐4)
Number of subjects: 30
Study 16339790 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg kg(‐1) h(‐1) (Group P‐6)
Number of subjects: 30
Study 16339790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P‐4 and P‐6)
Number of subjects: 30
Study 16339790 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with unbound propofol concentration
Number of subjects: 30
Study 14651992 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained subjects
Number of subjects: 0
Study 14651992 — intervention group
Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 0